Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Alpha2 adrenergic agonists for the management of opioid withdrawal

Esta versión no es la más reciente

ver la versión actual 03 mayo 2016

Información

DOI:
https://doi.org/10.1002/14651858.CD002024.pub2Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 18 octubre 2004see what's new
Tipo:
  1. Intervention
Etapa:
  1. Review
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Alcohol y drogas

Copyright:
  1. Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Linda Gowing

    Correspondencia a: Department of Clinical and Experimental Pharmacology, University of Adelaide, Adelaide, Australia

    [email protected]

  • Michael Farrell

    Institute of Psychiatry, National Addiction Centre, London, UK

  • Robert Ali

    Clinical and Experimental Pharmacology, Drug and Alcohol Services Council, Parkside, Australia

  • Jason M White

    Clinical & Experimental Pharmacology, University of Adelaide, Adelaide, Australia

Contributions of authors

Linda Gowing assessed each potentially relevant study according to identified inclusion and exclusion criteria. Inclusion and exclusion decisions were confirmed by discussion with co‐reviewers. Linda Gowing extracted key information from included studies and compiled a first draft of the review. Mike Farrell, Robert Ali and Jason White confirmed and commented on the review content.

Sources of support

Internal sources

  • Drug and Alcohol Services Council, South Australia, Australia.

External sources

  • Commonwealth Department of Health and Aged Care, Canberra, Australia.

Declarations of interest

None

Acknowledgements

Boehringer Ingelheim Pty Limited (Australia) and the Britannia Pharmaceutical Group provided information on trials involving clonidine and lofexidine, respectively. The assistance of Maria Chang (Boehringer Ingelheim), Len Cretney and Jackie Akhurst (Britannia Pharmaceuticals) is gratefully acknowledged.

Meredith Cameron (Cochrane Consumers' Network) provided comments on the synopsis.

Version history

Published

Title

Stage

Authors

Version

2016 May 03

Alpha<sub>2</sub>‐adrenergic agonists for the management of opioid withdrawal

Review

Linda Gowing, Michael Farrell, Robert Ali, Jason M White

https://doi.org/10.1002/14651858.CD002024.pub5

2014 Mar 31

Alpha<sub>2</sub>‐adrenergic agonists for the management of opioid withdrawal

Review

Linda Gowing, Michael F Farrell, Robert Ali, Jason M White

https://doi.org/10.1002/14651858.CD002024.pub4

2009 Apr 15

Alpha<sub>2</sub>‐adrenergic agonists for the management of opioid withdrawal

Review

Linda Gowing, Michael Farrell, Robert Ali, Jason M White

https://doi.org/10.1002/14651858.CD002024.pub3

2004 Oct 18

Alpha2 adrenergic agonists for the management of opioid withdrawal

Review

Linda Gowing, Michael Farrell, Robert Ali, Jason M White

https://doi.org/10.1002/14651858.CD002024.pub2

2003 Apr 22

Alpha2 adrenergic agonists for the management of opioid withdrawal

Review

Linda R. Gowing, Michael Farrell, Robert L Ali, Jason M White

https://doi.org/10.1002/14651858.CD002024

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.